On August 25, 2022 A drug discovered by Cancer Therapeutics CRC scientists reported that it has entered Phase 2 clinical trials (Press release, Canthera Discovery, AUG 25, 2022, View Source [SID1234618640]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Amplia Therapeutics Limited recently announced the recruitment of the first patient to the ACCENT trial, a Phase 1b/Phase 2a clinical trial of focal adhesion kinase inhibitor AMP945. The use of AMP945 in the trial is intended to enhance the efficacy of chemotherapy for people with advanced pancreatic cancer undergoing first-line treatment.

AMP945 was invented by scientists from the Cancer Therapeutics Cooperative Research Centre (2007-2020) and the program was licensed to Amplia Therapeutics to take into clinical development.